A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Phase 1 Completed 26 enrolled Gylden Pharma Ltd Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland · collab University of Lausanne Hospitals · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle. Note: Stage 1 of the 2-part adaptive trial, testing a specifically selected mix of Dengue virus peptides, commenced Aug 2021. This is now in follow up (NCT04935801).

Timeline

Start: 2022-01-10
Primary completion: 2022-09-15
Completion: 2022-09-15

Publications

Besson J, Audran R, Karlen M, Miauton A, Hajjami HM, Warpelin-Decrausaz L, Sene L, Schaufelberger S, Faivre V, Faouzi M, Hartley MA, Spertini F, Genton B. A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland. BMC Infect Dis. 2025 Apr 7;25(1):472. doi: 10.1186/s12879-025-10844-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PepGNP-COVID19	Vaccine	12.8 ug	Other
Subject	PepGNP-COVID19	Vaccine	38.3 ug	Other

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Summary

Timeline

Publications

Drugs

Indications